Press Releases
Page 8 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
MyOme Appoints Two Healthcare Leaders to Board as AI Genomics Platform Expands
MyOme strengthens its board with Sam Roosz and Dr. Ravi Thadhani appointments, bringing healthcare technology and clinical expertise to AI genomics platform.
SynbioTech's L. plantarum FS4722 Shows Promise for Hyperuricemia Prevention in Preclinical Studies
SynbioTech's probiotic strain L. plantarum FS4722 demonstrates potential for hyperuricemia prevention through gut-liver-kidney axis modulation in preclinical trials.
Global Nasal Sprays Market Projected to Reach $29.7 Billion by 2036 as Allergy Cases Rise
The global nasal sprays market will grow from $16.8 billion in 2026 to $29.7 billion by 2036, driven by rising allergic rhinitis cases and non-oral delivery preferences.
Andelyn Biosciences Partners with ENCell to Expand Gene Therapy Manufacturing in Asia-Pacific
Andelyn Biosciences and ENCell form strategic partnership to enhance global gene therapy manufacturing capabilities and expand access to treatments.
Turbine Partners with Crown Bioscience to Advance AI-Powered Cancer Drug Discovery Using Organoid Technology
Turbine and Crown Bioscience announce strategic partnership combining AI virtual screening with organoid tumor models to accelerate oncology research and drug development.
GHIT Fund Invests $8.5 Million in Malaria and NTD Drug Development with GSK, Eisai Partners
GHIT Fund announces $8.5 million investment across five R&D projects for malaria and neglected tropical disease treatments with major pharma partners.
GHIT Fund Invests $8.5 Million in Malaria and Neglected Tropical Disease Drug Development with GSK, Eisai Partners
GHIT Fund announces $8.5M investment across five R&D projects targeting malaria and neglected tropical diseases with pharmaceutical partners.
PeptiDream Partner Asahi Kasei Therapeutics Initiates Phase 1 Clinical Trial for AK1940
Asahi Kasei Therapeutics begins Phase 1 clinical trial for AK1940, developed through collaboration with PeptiDream Inc., marking key milestone in drug development.
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Biogen consolidates global felzartamab rights through strategic acquisition from TJ Biopharma, expanding CD38-directed antibody reach in China market.
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Argo Biopharma doses first patients in Phase II trials of BW-40202, an investigational siRNA therapy targeting complement factor B for PNH and IgAN treatment.
Mabwell Bioscience Passes First PIC/S Member GMP Inspection for Denosumab Biosimilars in Jordan
Mabwell Bioscience achieves milestone regulatory approval as Jordan FDA clears GMP inspection for two denosumab biosimilars, expanding global reach.